Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia-Reference-Cited by-同舟云学术

Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia

Published:2010-06-05 Issue:11 Volume:89 Page:1073-1080
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Peñalver Francisco Javier, ,Alvarez-Larrán Alberto,Díez-Martin Jose Luis,Gallur Laura,Jarque Isidro,Caballero Dolores,Díaz-Mediavilla Joaquín,Bustelos Rosalía,Fernández-Aceñero María Jesús,Cabrera José Rafael

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-010-0997-y.pdf

Reference33 articles.

1. Gehrs BC, Friedberg RC (2002) Autoimmune hemolytic anemia. Am J Hematol 69:258–271

2. King KE, Ness PM (2005) Treatment of autoimmune haemolytic anemia. Semin Hematol 42:131–136

3. Petz LD (2001) Treatment of autoimmune hemolytic anemias. Curr Opin Hematol 8:411–416

4. Garvey B (2008) Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 141(2):149–169

5. Semple JW, Freedman J (2005) Autoimmune pathogenesis and autoimmune hemolytic anemia. Semin Hematol 42:122–130

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double‐blind, placebo‐controlled, global study (FORWARD);American Journal of Hematology;2023-11-06

2. Antibody based therapeutics for autoimmune hemolytic anemia;Expert Opinion on Biological Therapy;2023-11

3. Unusual complications in the management of chronic lymphocytic leukemia;American Journal of Hematology;2022-05-12

4. Development of New Drugs for Autoimmune Hemolytic Anemia;Pharmaceutics;2022-05-11

5. Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study;American Journal of Hematology;2022-03-03